We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

37 hedge funds and large institutions have $290M invested in Benitec Biopharma in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

23% more funds holding

Funds holding: 30 → 37 (+7)

21% more capital invested

Capital invested by funds: $240M → $290M (+$50M)

4.07% more ownership

Funds ownership: 81.82% → 85.89% (+4.1%)

Holders
37
Holders Change
+7
Holders Change %
+23.33%
% of All Funds
0.5%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
10
Increased
16
Reduced
6
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$11.1M
2
IAM
Infinitum Asset Management
Florida
+$11.1M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.66M
4
SCM
Silverarc Capital Management
Massachusetts
+$3.02M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.44M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$951K
2
6CM
683 Capital Management
New York
-$452K
3
Morgan Stanley
Morgan Stanley
New York
-$190K
4
Citigroup
Citigroup
New York
-$76.3K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$22.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
State Street
26
State Street
Massachusetts
$276K +$61.7K +5,100 +32%
Qube Research & Technologies (QRT)
27
Qube Research & Technologies (QRT)
United Kingdom
$247K -$22.9K -1,893 -9%
UBS Group
28
UBS Group
Switzerland
$130K +$60.5K +4,999 +100%
SG Americas Securities
29
SG Americas Securities
New York
$110K +$102K +8,458 New
Citigroup
30
Citigroup
New York
$80.1K -$76.3K -6,308 -51%
GI
31
GAMMA Investing
California
$77.6K -$5.79K -479 -7%
Balyasny Asset Management
32
Balyasny Asset Management
Illinois
$36.6K +$34.1K +2,816 New
Acadian Asset Management
33
Acadian Asset Management
Massachusetts
$23K +$22K +1,817 New
Bank of America
34
Bank of America
North Carolina
$3.8K +$1.74K +144 +97%
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$3K +$423 +35 +20%
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$2.42K – – –
Group One Trading
37
Group One Trading
Illinois
$1.16K – – –
6CM
38
683 Capital Management
New York
– -$452K -35,817 Closed
TRCT
39
Tower Research Capital (TRC)
New York
– -$13.9K -1,099 Closed
NA
40
NewEdge Advisors
Louisiana
– -$8.48K -671 Closed
1
2

BNTC Hedge Fund Activity: Q1 2025 in Review

37 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2025, worth a combined $290M — up 21% from $240M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new BNTC positions and 3 closed out — a net gain of 7 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was Suvretta Capital Management, adding an estimated $11.1M. The largest seller was Franklin Resources, cutting an estimated $951K.

  • 37 institutional investors held Benitec Biopharma (BNTC) as of Q1 2025, up from 30 in Q4 2024.
  • Funds reported $290M of Benitec Biopharma stock for Q1 2025, up 21% quarter-over-quarter.
  • 10 funds opened new Benitec Biopharma positions in Q1 2025 and 3 closed out, a net change of +7 holders.
  • The largest Benitec Biopharma buyer in Q1 2025 was Suvretta Capital Management, an estimated $11.1M added.
  • The largest Benitec Biopharma seller in Q1 2025 was Franklin Resources, an estimated $951K sold.

Based on aggregated 13F filings for Q1 2025.